Injection of autologous volar fibroblasts to the stump site to allow pressure adaptation and enhanced prosthetic use in amputees
- Institution
- Johns Hopkins University, MD
- Principal investigator
- Luis Andres Garza
- Funding
- $519K
- Duration
- 2021–2027
Moonbase score
Still being scored
Abstract
Project Summary Abstract The long term objective of the proposed research is to use cellular therapy to advance regenerative medicine. In particular, we wish to help amputees who have lost a limb. While major improvements have been made to prosthetics, the skin side of the interface at the stump site was not evolved to bear weight. The stump does not normally have the pressure adaptive abilities of the soles of the foot for example. The present grant proposes to biopsy, purify and expand fibroblasts from an existing palm or sole and inject them into the stump site of an amputee to improve their use of prosthetics. We also propose to study the basic biology behind cell therapy to understand how the injected cells change the native cells, and in turn how those native cells affect the injected cells. The results of this grant will hopefully lead to a new therapy to help not only amputees, but potentially prevent pressure ulcers and provide a platform for future cell therapies.
LOADING MOONBASE SCORE
Questions for Johns Hopkins University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Johns Hopkins UniversityNot yet scored
Inhibition of regeneration restraining pathways to promote healing
Luis Andres Garza · $649K · 2025–2030
- NIH · Johns Hopkins UniversityNot yet scored
Future Academic Scientists in Dermatology
Luis Andres Garza · $270K · 2020–2026
- NIH · Johns Hopkins University72
Development, Piloting and Dissemination of an Integrated Clinical and Social Multi-level Decision Support Platform to Address Social Determinants of Health Among Minority Populations in Baltimore City
Elham Hatef-Naimi · $611K · 2021–2025